- Home
- LDWY vs BMRA Comparison
LDWY vs BMRA Comparison
Compare LDWY & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- BMRA
- Stock Information
- Founded
- LDWY 1990
- BMRA 1971
- Country
- LDWY United States
- BMRA United States
- Employees
- LDWY N/A
- BMRA N/A
- Industry
- LDWY Advertising
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LDWY Consumer Discretionary
- BMRA Health Care
- Exchange
- LDWY Nasdaq
- BMRA Nasdaq
- Market Cap
- LDWY 9.2M
- BMRA 8.2M
- IPO Year
- LDWY 1991
- BMRA N/A
- Fundamental
- Price
- LDWY $4.95
- BMRA $2.92
- Analyst Decision
- LDWY
- BMRA
- Analyst Count
- LDWY 0
- BMRA 0
- Target Price
- LDWY N/A
- BMRA N/A
- AVG Volume (30 Days)
- LDWY 5.7K
- BMRA 425.8K
- Earning Date
- LDWY 08-28-2025
- BMRA 10-14-2025
- Dividend Yield
- LDWY N/A
- BMRA N/A
- EPS Growth
- LDWY N/A
- BMRA N/A
- EPS
- LDWY 1.66
- BMRA N/A
- Revenue
- LDWY $71,244,000.00
- BMRA $5,311,000.00
- Revenue This Year
- LDWY N/A
- BMRA N/A
- Revenue Next Year
- LDWY N/A
- BMRA N/A
- P/E Ratio
- LDWY $3.06
- BMRA N/A
- Revenue Growth
- LDWY 187.12
- BMRA N/A
- 52 Week Low
- LDWY $3.02
- BMRA $2.08
- 52 Week High
- LDWY $6.19
- BMRA $10.16
- Technical
- Relative Strength Index (RSI)
- LDWY 41.34
- BMRA 43.27
- Support Level
- LDWY $4.64
- BMRA $2.87
- Resistance Level
- LDWY $5.35
- BMRA $3.08
- Average True Range (ATR)
- LDWY 0.33
- BMRA 0.21
- MACD
- LDWY -0.08
- BMRA 0.01
- Stochastic Oscillator
- LDWY 20.00
- BMRA 54.93
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.